Forefront Analytics, LLC
- SEC CIK
- 0001696802
- Latest filing
- Aug 12, 2026
EIGR holding history
Eiger BioPharmaceuticals, Inc. in every 13F filed by Forefront Analytics, LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
EIGR overviewAll 13F holders of EIGRFull Q2 2026 holdings
- Shares (Q2 2023)
- 0
- Sold out in Q2 2023
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 8
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2023 | 0 | $0 | 0.0% | −51,679−100.0% | Sold out | Holders |
| Q1 2023 | 51,679 | $46.3K | <0.1% | +39,300+317.5% | Added | Holders |
| Q4 2022 | 12,379 | $14.6K | <0.1% | +12,379 | New | Holders |
| Q3 2022 | 0 | $0 | 0.0% | −11,527−100.0% | Sold out | Holders |
| Q2 2022 | 11,527 | $73.0K | <0.1% | +700+6.5% | Added | Holders |
| Q1 2022 | 10,827 | $87.0K | <0.1% | +475+4.6% | Added | Holders |
| Q4 2021 | 10,352 | $58.0K | <0.1% | +275+2.7% | Added | Holders |
| Q3 2021 | 10,077 | $68.0K | <0.1% | +50+0.5% | Added | Holders |
| Q2 2021 | 10,027 | $82.0K | <0.1% | −736−6.8% | Reduced | Holders |
| Q1 2021 | 10,763 | $97.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.